Open company graph database — free web & API
Login

Genentech, Inc.

ジェネンテック株式会社Alias
Ticker
—
Listed market
—
Country
United States of America
Employees (consolidated)
20,000
Related companies
2
§01

Basic information

BASIC
Head office
South San Francisco, CA
Chief executive
John Doe
Employees (non-consolidated)
10,000 people
Employees (consolidated)
20,000 people
Start date
2009-01-01
End date
§02

Websites

1 DOMAINS
§03

Business

4
Patient Support ServicesClinical TrialsMedicine Information SupportOur Medicines & Products
§04

Related companies

2 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Citibank
Bank
Legacy Pharma Inc
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§07

News

533 ARTICLES

FDA Approves Genentech’s WILSERDLYSources

The FDA has approved Genentech’s WILSERDLY (giredestrant), a next‑generation oral SERD, for the treatment of ER‑positive, ESR1‑mutated advanced breast cancer. In the Phase III evERA trial, WILSERDLY combined with everolimus significantly delayed disease progression or death by 62% compared with standard endocrine therapy plus everolimus in patients with ESR1 mutations. ESR1 mutations, detected by an FDA‑approved test, are a major cause of hormone‑therapy resistance in up to 40% of patients.

Gazyva, First FDA-Approved Drug for Primary Membranous NephropathySources

Genentech's Gazyva became the first FDA-approved treatment for primary membranous nephropathy (pMN). In the Phase III MAJESTY trial, the complete remission rate of proteinuria at two years was 36.1% versus 5.7% for tacrolimus, showing a statistically significant advantage. This approval underscores the importance of B-cell-targeted therapy in immune-mediated kidney diseases.

Genentech & Roche Present New AD Data at CTADSources

Genentech and Roche disclosed updated Phase Ib/IIa Brainshuttle™ AD study results for trontinemab, showing rapid amyloid removal and biomarker changes. They also outlined Phase III PrevenTRON design for preclinical Alzheimer’s disease and Phase II TARBELA-AD study of oral NLRP3 inhibitor RG6434 targeting neuroinflammation, alongside global clinical and health economic data for Elecsys®.

Divarasib Shows Strong KRAS G12C ResultsSources

In the Phase III Krascendo 1 study, divarasib monotherapy reduced the risk of disease progression or death by 42% and the risk of death by 44% compared with first-generation KRAS G12C inhibitors. Median overall survival was approximately 18 months with divarasib, versus 12 months with sotorasib or adagrasib. No new safety signals were observed, and the most common treatment-related adverse events were mainly low grade and manageable.

Genentech Sefaxersen Reduces ProteinuriaSources

Genentech reported interim Phase III data showing that the antisense oligonucleotide Sefaxersen reduced proteinuria by 43.1% versus placebo at 37 weeks. The drug, the first ASO evaluated in IgA nephropathy, inhibits complement factor B production and may slow disease progression by reducing kidney inflammation. It is designed as a once‑monthly subcutaneous injection for patient convenience.

Genentech Announces Neuroimmunology DataSources

Genentech presented new pivotal trial data at MSToronto2026, showing Fenebrutinib’s therapeutic effect on chronic active lesions and a 55% reduction in annualized relapse rate versus an active comparator. Ocrevus OPERETTA 2 Phase III data demonstrated that 90% of children aged 10–17 remained relapse‑free over two years, underscoring consistent MS control across ages. Enspryng METEOROID Phase III data were also highlighted in the presentation.

Genentech to Present ESMO 2026 DataSources

Genentech will present late-stage lung and breast cancer data at ESMO 2026. Phase III results showed divarasib was superior to first-generation KRAS G12C inhibitors in previously treated advanced KRAS G12C-mutated non-small cell lung cancer. Patient-reported outcomes from the Phase III lidERA study showed improved efficacy with giredestrant over standard endocrine therapy without compromising tolerability or health-related quality of life in early-stage breast cancer.

FDA Approves Genentech’s Enspryng for TEDSources

The FDA has approved Genentech’s Enspryng (satralizumab‑mwge), a first‑in‑class IL‑6R inhibitor, as the first and only at‑home subcutaneous treatment for thyroid eye disease (TED). Phase III SatraGO‑1 and SatraGO‑2 studies showed significant reductions in proptosis and diplopia with a favorable safety profile, regardless of disease activity or duration. Enspryng offers patients a flexible, quarterly at‑home maintenance option.

Vamikibart Shows 52-Week UME BenefitsSources

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with uveitic macular edema (UME) at 52 weeks.

FDA Approves Tecentriq for Colon CancerSources

The FDA approved Genentech’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of a certain type of stage III colon cancer. The approval was based on the Phase III ATOMIC study, published in The New England Journal of Medicine, which found the combination reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone.

§09

Sources & updates

SOURCES
↑